The key facts about the biomanufacturing sector

Published on November 27, 2025 by Soraya Sandokchi

👉 France asserts its leadership in spin-outs, but struggles to move on to scale-ups

The European Spin-out Report 2025, published on Thursday, ranks the CNRS as the leading European research center generating deep tech and life sciences spin-outs. Inserm and CEA come in fourth and third place, respectively. Inria (8th), the Institut Pasteur (9th), and Inrae (11th) also feature in the top 20. When it comes to universities, however, France lags behind somewhat, with Paris-Saclay in 13th place, PSL (16th), and the Sorbonne (19th). The study also highlights a well-known obstacle in France: the difficulty spin-outs have in accessing funding. At the same time, other countries are successfully launching high-profile biotech companies in the field of innovative therapies, such as gene therapy specialist UniQure (a spin-off from Amsterdam UMC) and Abcam (University of Cambridge), which produces antibodies for research. 


👉 The Climbin project innovates in bioprocess monitoring

Led by the University of Tours, in collaboration with the LRGP laboratory in Nancy, Servier, equipment manufacturer INDATECH, and Ondalys, the Climbin project on real-time monitoring of cell cultures is moving forward with two articles published this year.

The first project demonstrates the effectiveness of Raman spectroscopy coupled with machine learning for real-time, in situ monitoring of CHO cell cultures in 10-liter bioreactors. The second presents a method for online prediction of critical quality attributes (CQAs) of monoclonal antibodies produced by CHO cells, based on Raman spectra processed by DUPLEX–PLS modeling. The Climbin project aims in particular to reduce the production costs of cell therapies.


👉 US lawmakers prepare a Biomanufacturing Excellence Act

The Biomanufacturing Excellence Act has been introduced in Congress with the goal of creating a National Center of Excellence in Biopharmaceutical Biomanufacturing. Led by the National Institute for Standards and Technology (NIST), this public-private center will enable manufacturers to test innovative manufacturing methods, improve regulatory understanding, and support the development of skills in the sector through practical training. The initiative aims to strengthen the United States' autonomy in the manufacture of critical biomedicines in response to national security, health, and economic challenges.